Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Company Reports
Hansa Biopharma
Hansa Biopharma
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
No data
Company Revenue
No data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name
Drug Name
Approved
Patent Expires
Indication
Idefirix
Imlifidase
2020-08-25
Kidney transplantation
,
Immunologic desensitization
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Imlifidase
healthy volunteers/patients
,
duchenne muscular dystrophy
,
kidney diseases
,
graft rejection
,
renal insufficiency
,
guillain-barre syndrome
,
thrombotic thrombocytopenic purpura
,
thrombocytopenic purpura
,
purpura
,
retinal diseases
,
chronic renal insufficiency
,
crigler-najjar syndrome
,
kidney transplantation
,
chronic kidney failure
,
anti-glomerular basement membrane disease
,
psychology rejection
Lornoxicam
myelodysplastic syndromes
,
myeloid leukemia acute
,
graft vs host disease
,
precursor cell lymphoblastic leukemia-lymphoma
,
bcr-abl positive chronic myelogenous leukemia
Bevifimod
chronic hepatitis b
,
chronic hepatitis
,
hepatocellular carcinoma
,
liver neoplasms
Corticorelin
chronic renal insufficiency
,
chronic kidney failure
,
kidney diseases
Globulin, immune
neoplasms
,
non-small-cell lung carcinoma
Bos taurus adrenal cortex corticosteroids
knee osteoarthritis
,
osteoarthritis
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use